These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 34719075)
21. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148 [TBL] [Abstract][Full Text] [Related]
22. EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation. Mo SJ; Hou X; Hao XY; Cai JP; Liu X; Chen W; Chen D; Yin XY Cancer Commun (Lond); 2018 Apr; 38(1):9. PubMed ID: 29764501 [TBL] [Abstract][Full Text] [Related]
23. URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-κB signaling pathway. Xing S; Zhang B; Hua R; Tai WC; Zeng Z; Xie B; Huang C; Xue J; Xiong S; Yang J; Liu S; Li H BMC Cancer; 2015 May; 15():368. PubMed ID: 25947641 [TBL] [Abstract][Full Text] [Related]
24. Knockdown of PHF5A Inhibits Migration and Invasion of HCC Cells via Downregulating NF- Yang Q; Zhang J; Xu S; Jia C; Meng W; Tang H; Zhang X; Zhang Y; Fu B Biomed Res Int; 2019; 2019():1621854. PubMed ID: 30766880 [TBL] [Abstract][Full Text] [Related]
25. MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Zhao N; Wang R; Zhou L; Zhu Y; Gong J; Zhuang SM Mol Cancer; 2014 Feb; 13():35. PubMed ID: 24565101 [TBL] [Abstract][Full Text] [Related]
26. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Kuo TC; Lu HP; Chao CC Biochem Pharmacol; 2011 Jul; 82(2):184-94. PubMed ID: 21549688 [TBL] [Abstract][Full Text] [Related]
27. SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma. Lin L; Chen S; Wang H; Gao B; Kallakury B; Bhuvaneshwar K; Cahn K; Gusev Y; Wang X; Wu Y; Marshall JL; Zhi X; He AR Theranostics; 2021; 11(9):4232-4250. PubMed ID: 33754058 [No Abstract] [Full Text] [Related]
28. PIGU promotes hepatocellular carcinoma progression through activating NF-κB pathway and increasing immune escape. Wei X; Yang W; Zhang F; Cheng F; Rao J; Lu L Life Sci; 2020 Nov; 260():118476. PubMed ID: 32971102 [TBL] [Abstract][Full Text] [Related]
29. MiR-16 inhibits hepatocellular carcinoma progression by targeting FEAT through NF-κB signaling pathway. Su XF; Li N; Meng FL; Chu YL; Li T; Gao XZ Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10274-10282. PubMed ID: 31841182 [TBL] [Abstract][Full Text] [Related]
30. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1. Guo XL; Wang HB; Yong JK; Zhong J; Li QH Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839 [TBL] [Abstract][Full Text] [Related]
31. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma. Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343 [TBL] [Abstract][Full Text] [Related]
32. Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells. Chiang IT; Liu YC; Wang WH; Hsu FT; Chen HW; Lin WJ; Chang WY; Hwang JJ In Vivo; 2012; 26(4):671-81. PubMed ID: 22773582 [TBL] [Abstract][Full Text] [Related]
33. NFKBIZ regulates NFκB signaling pathway to mediate tumorigenesis and metastasis of hepatocellular carcinoma by direct interaction with TRIM16. Guo D; Zhang M; Wei T; Zhang X; Shi X; Tang H; Ding M; Li J; Zhang S; Guo W Cell Mol Life Sci; 2024 Apr; 81(1):167. PubMed ID: 38581570 [TBL] [Abstract][Full Text] [Related]
34. ING4 suppresses hepatocellular carcinoma via a NF-κB/miR-155/FOXO3a signaling axis. Qian F; Hu Q; Tian Y; Wu J; Li D; Tao M; Qin L; Shen B; Xie Y Int J Biol Sci; 2019; 15(2):369-385. PubMed ID: 30745827 [TBL] [Abstract][Full Text] [Related]
35. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700 [TBL] [Abstract][Full Text] [Related]
36. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. Son Y; Shin NR; Kim SH; Park SC; Lee HJ Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373 [TBL] [Abstract][Full Text] [Related]
37. CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-κB oncogenic signaling. Hu B; Xu Y; Li YC; Huang JF; Cheng JW; Guo W; Yin Y; Gao Y; Wang PX; Wu SY; Zhou J; Fan J; Yang XR Clin Transl Med; 2020 Dec; 10(8):e233. PubMed ID: 33377659 [TBL] [Abstract][Full Text] [Related]
38. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054 [TBL] [Abstract][Full Text] [Related]
39. Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma. Brunetti M; Holth A; Panagopoulos I; Staff AC; Micci F; Davidson B Virchows Arch; 2019 Feb; 474(2):177-185. PubMed ID: 30467600 [TBL] [Abstract][Full Text] [Related]
40. miR-17-5p and miR-20a-5p suppress postoperative metastasis of hepatocellular carcinoma via blocking HGF/ERBB3-NF-κB positive feedback loop. Liu DL; Lu LL; Dong LL; Liu Y; Bian XY; Lian BF; Xie L; Wen D; Gao DM; Ke AW; Fan J; Wu WZ Theranostics; 2020; 10(8):3668-3683. PubMed ID: 32206115 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]